— Collaboration enables creation of PDCs using CytomX's Probody Platform and ImmunoGen's ADC technology —
Under the terms of the agreement, the companies will collaborate to develop PDCs against a defined number of targets. This collaboration brings together CytomX's proprietary antibody masking technology and tumor-selective protease substrates with ImmunoGen's highly potent ADC cell-killing agents and engineered linkers.
Each company retains full development control of PDC compounds resulting from its target selection and is responsible for preclinical and clinical testing, manufacturing, and commercialization. Each company is entitled to potentially receive clinical and post-approval milestone payments from the other company, as well as royalties on the sales of any marketed products resulting from this collaboration.
"This strategic collaboration with ImmunoGen is designed to allow each
company to build pipeline value by capitalizing on the best of both
technology platforms," said
"ImmunoGen is committed to developing better therapies for the treatment
of patients with cancer," commented
CytomX's Probodies are masked monoclonal antibodies that are designed to remain inert in healthy tissue but be activated specifically in the disease microenvironment. Through precise targeting of the disease microenvironment, Probodies have the potential to address diseases in ways that have not been possible to-date, enabling a new level of tissue targeting, selectivity and activation.
ImmunoGen's ADC technology is used in Roche's Kadcyla® and in multiple other ADC compounds now in clinical and preclinical testing. It includes highly potent cancer-cell killing agents developed specifically for targeted delivery to cancer cells using monoclonal antibodies, and linkers engineered to keep the agent attached to the antibody in the blood stream and control its release and activation inside a cancer cell.
CytomX Therapeutics, the Probody™ therapeutics company, is dedicated to
transforming lives with safer, more effective therapies. CytomX's
Probody Platform represents a disruptive approach to discovering and
developing the next generation of antibody therapeutics and is enabling
the development of a diversified pipeline in major unmet medical needs
including cancer and inflammation. CytomX is led by a seasoned and
proven management team and is financed by leading life science investors
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including PDCs. A review of these risks can be found in ImmunoGen's
Annual Report on Form 10-K for the fiscal year ended
Contacts for CytomX:
Executive Director, Investor Relations
and Corporate Communications
The Yates Network
News Provided by Acquire Media